Altus Formulation Inc.
http://www.altusformulation.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Altus Formulation Inc.
Altus And Spektar Launch New Value-Added Medicines Firm Spektus Pharma
Altus’ breakable extended-release tablet technology will be Spektus’ holy grail in developing novel and differentiated therapies in the psychiatry space.
Zohydro Approval Haunts FDA Panelist At Vantrela Meeting
Teva's comparative data suggesting its Vantrela is less attractive to abusers validates advisory committee recommendation in 2012 against Zohydro's approval, advisory committee member says.
Biopharma Quarterly Dealmaking Statistics, Q1 2015
Biopharma financing reached $15.1 billion, with record-breaking FOPO dollar volume making up close to $10 billion of the total; AbbVie topped the $66.5 billion M&A activity with its $20 billion buy of Pharmacyclics; and gastroenterology was one of the most highly partnered therapeutic areas.
Abuse-Deterrent Opioids: FDA Regulatory Options Aired At Meeting
Brand industry favors two- to three-year period for withdrawal or reformulation of products without abuse-deterrent features, while generic industry calls for expedited review pathway. Purdue and Zogenix agree to waive three-year market exclusivity for their respective hydrocodone products.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice